Weekly paclitaxel in heavily pretreated ovarian cancer patients: Does this treatment still provide further advantages?

Objective To evaluate the disease control rate (DCR) in heavily pretreated and relapsed ovarian cancer patients re-challenged with a weekly paclitaxel schedule and to establish whether a correlation between dose intensity, progression-free interval (PFI) and overall survival (OS) exists. Methods Retrospective data were collected from 30 heavily pretreated metastatic ovarian cancer patients who received 80 mg/m²/week paclitaxel regimen. Results The treatment was well tolerated and showed a DCR in 70% of the patients, with only one case of grade 3 hematological toxicity. One patient (3%) showed a complete response, 15 patients (50%) a partial response and five patients (17%) a stabilization of their disease. The regimen was mostly used as a fourth-line chemotherapy (range 2-7). The median dose intensity in responding patients was 57.5 mg/m²/week and in those with progressive disease 49.7 mg/m²/week. (p = 0.20). PFI and OS were increased in the responder patient groups with a log-rank test of 25.64 (p <0.001) and 15.10 (p = 0.0001), respectively. Conclusions Weekly administration of paclitaxel was active and well tolerated as a salvage therapy for heavily pretreated ovarian cancer patients.